Saccharomyces boulardii, a novel yeast probiotic ameliorates metabolic syndrome associated with PCOS: A preliminary study
DOI:
https://doi.org/10.55184/ijpas.v75i03.194Keywords:
Polycystic ovary syndrome, Saccharomyces boulardii, Insulin resistance, Letrozole, Gut microbiota, Probiotics, Metabolic syndrome.Abstract
age accompanied by metabolic alteration. Gut microbiota has been found to play a critical role in the pathophysiology and further
progression of PCOS. The wide range of side effects of existing medical management have made it necessary to continuously look for
an efficient and safe alternative. Saccharomyces boulardii, the only eukaryotic probiotic with its unique properties is becoming very
popular as the only yeast probiotic. Hypothesis: This preliminary study evaluated the efficacy of S. boulardii on a PCOS-IR (PCOS with
insulin resistance) rat model. Materials and methods: PCOS was induced in all virgin female Wistar rats with 1 mg/kg/day of letrozole
and high fat (40%) diet except for the control group for 21 days. The rats were then co-administered with lyophilized S. boulardii of
1.8×107 CFU /kg/Day. Results: S. boulardii prevented the further progression of PCOS by restoring the ovarian morphology and metabolicparameters. Conclusion: However, this mechanism can be attributed by the possible correction of dysbiosis and metabolic alterationin PCOS by S. boulardii.
